In 2023, the 340B covered entities purchased $66.3 billion in covered outpatient drugs through the program, compared to $2.4 billion in 2005.

Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.

The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...

While he didn’t decide whether rebate models are permissible under the 340B statute, the judge granted Sanofi a partial win by directing HRSA to reconsider the company’s rebate model, which it ...

A federal judge has rejected Johnson & Johnson’s challenge to block its proposed rebate model under the 340B Drug Pricing Program, Bloomberg Law reported June 27. Judge Rudolph Contreras of the U.S.

Specifically, BMS is taking issue with a decision to deny its rebate plan for big-selling blood thinner Eliquis (apixaban) under the 340B federal drug discount programme – which requires ...

HHS Secretary Robert F. Kennedy Jr. abruptly removed 17 vaccine experts from the CDC’s Advisory Committee on Immunization Practices on Monday — and Washington is already reeling.

Eli Lilly, Bristol Myers Squibb, Sanofi and Novartis all took to the courts this year against HRSA after it stopped them from implementing plans to pay hospitals after-the-fact rebates for 340B ...